Tauopathy

Pathway Diagram

flowchart TD
    Tauopathy["Tauopathy"]
    style Tauopathy fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Alzheimer["Alzheimer"]
    Tauopathy -->|"associated with"| Alzheimer
    Neurodegeneration["Neurodegeneration"]
    Tauopathy -->|"associated with"| Neurodegeneration
    Tauopathy -->|"activates"| Alzheimer
    Tauopathy -->|"activates"| Neurodegeneration
    Tauopathy -->|"activates"| Tauopathy
    Tauopathy -->|"associated with"| Tauopathy
    Autophagy["Autophagy"]
    Tauopathy -->|"activates"| Autophagy
    Tauopathy -->|"expressed in"| Tauopathy
    MICROGLIA["MICROGLIA"]
    MICROGLIA -->|"activates"| Tauopathy
    NEURODEGENERATIVE_DISEASES["NEURODEGENERATIVE DISEASES"]
    NEURODEGENERATIVE_DISEASES -->|"activates"| Tauopathy
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    ALZHEIMER_S_DISEASE -->|"activates"| Tauopathy
    NEURODEGENERATION["NEURODEGENERATION"]
    NEURODEGENERATION -->|"activates"| Tauopathy
    TAU["TAU"]
    TAU -->|"activates"| Tauopathy
    NEURODEGENERATION -->|"associated with"| Tauopathy
    ALZHEIMER_S_DISEASE -->|"associated with"| Tauopathy
    TAU -->|"associated with"| Tauopathy
    style Alzheimer fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,color:#e0e0e0
    style Autophagy fill:#5d4400,stroke:#4fc3f7,color:#e0e0e0
    style MICROGLIA fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style NEURODEGENERATIVE_DISEASES fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style ALZHEIMER_S_DISEASE fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style NEURODEGENERATION fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0
    style TAU fill:#1b5e20,stroke:#4fc3f7,color:#e0e0e0

Overview

Tauopathy refers to a class of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated tau protein within neurons and glial cells^{1Lancet (2005)2005 · DOI 10.1016/S0140-6736(05Open reference}. These disorders include Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), corticobasal syndrome (CBD), Pick’s disease, and chronic traumatic encephalopathy (CTE)^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}. The tau protein, encoded by the MAPT (Microtubule-Associated Protein Tau) gene, plays essential roles in microtubule stabilization, axonal transport, and synaptic function^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}.

The fundamental pathology in tauopathies involves the aggregation of tau into insoluble fibrils that form neurofibrillary tangles (NFTs), neuropil threads, and dystrophic neurites. These aggregates disrupt neuronal function through multiple mechanisms including microtubule destabilization, impaired axonal transport, synaptic dysfunction, and eventual neuronal death^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}.

Tau Protein Biology

Structure and Isoforms

The human MAPT gene located on chromosome 17q21.31 encodes the tau protein through alternative splicing of exon 10. Six tau isoforms are expressed in the adult brain, distinguished by the presence of 3 or 4 microtubule-binding repeats (3R or 4R tau) and 0, 1, or 2 N-terminal inserts^{5Neuron (1989)1989 · DOI 10.1016/0896-6273(89Open reference}:

• 3R tau isoforms: Exclude exon 10, contain 3 microtubule-binding repeats

• 4R tau isoforms: Include exon 10, contain 4 microtubule-binding repeats

In the normal adult brain, the ratio of 3R to 4R tau is approximately 1:1, reflecting balanced splicing regulation^{6J Neurochem (2011)2011 · DOI 10.1111/j.1471-4159.2011.07201.xOpen reference}. This balance is critical, as dysregulation toward 4R predominance is a hallmark of PSP and CBD, while 3R predominance characterizes Pick’s disease.

Tau Isoform Functions

Tau performs several essential neuronal functions:

1. Microtubule stabilization: The microtubule-binding repeats (R1-R4) bind to and stabilize microtubules, enabling axonal transport^{7Proc Natl Acad Sci USA (1975)1975 · DOI 10.1073/pnas.72.5.1858Open reference}.

2. Axonal transport regulation: Tau modulates the function of motor proteins (kinesin, dynein) that transport cargo along microtubules^{8J Cell Biol (2002)2002 · DOI 10.1083/jcb.200201075Open reference}.

3. Synaptic function: Tau localizes to synapses where it participates in neurotransmitter release and synaptic plasticity^{9J Exp Med (2012)2012 · DOI 10.1084/jem.20111339Open reference}.

4. Signal transduction: Tau interacts with various signaling molecules, including Src family kinases and phosphatases^{10J Neurosci (2011)2011 · DOI 10.1523/JNEUROSCI.5241-10.2011Open reference}.

Molecular Mechanisms of Tauopathies

Tau Hyperphosphorylation

Hyperphosphorylation is the primary modification that converts tau from a functional microtubule-stabilizing protein into a pathological aggregation-prone species^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}0. Over 45 serine, threonine, and tyrosine residues can be phosphorylated on tau, with specific phosphorylation patterns correlating with disease progression.

Key kinases regulating tau phosphorylation:

Key phosphatases:

• PP2A: The major phosphatase dephosphorylating tau; its activity is reduced in tauopathies^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}1

Tau Aggregation

The aggregation of tau into fibrils follows a nucleation-dependent polymerization model^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}2:

1. Nucleation: Formation of oligomeric tau species requires overcoming an energy barrier. This is accelerated by:

   • Hyperphosphorylation at specific sites (Thr231, Ser396)

   • Conformational changes exposing hydrophobic hexapeptide motifs (^306^VQIVYK^311^, ^378^VQIVLK^383^)

   • Interaction with seeding-competent tau fibrils

2. Elongation: Addition of monomeric tau to growing fibrils. 4R tau aggregates faster than 3R due to additional hexapeptide motifs in the fourth repeat.

3. Maturation: Formation of stable, protease-resistant fibrils with cross-β sheet architecture.

Tau Strain Diversity

Distinct tau fibril structures (strains) characterize different tauopathies, as revealed by cryo-electron microscopy^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}3:

Alzheimer’s disease:

• Paired helical filaments (PHFs)

• Straight filaments (SFs)

• 3R and 4R tau combined in filaments

Progressive supranuclear palsy:

• Three-layered helical structure

• C-shaped cross-section

• 4R tau predominant

Corticobasal syndrome:

• Four-layered structure

• More compact conformation

• Variable filament morphologies

Pick’s disease:

• Distinct filament architecture

• 3R tau predominant

Classification of Tauopathies

Primary Tauopathies (4R)

These disorders feature predominant 4R tau accumulation:

• Progressive Supranuclear Palsy (PSP): Characterized by Richardson’s syndrome, parkinsonism, vertical gaze palsy, and frontal cognitive deficits^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}4

• Corticobasal Syndrome (CBS): Features asymmetric parkinsonism, apraxia, alien limb phenomenon, and cortical sensory loss^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}5

• Argyrophilic Grain Disease (AGD): Late-onset dementia with argyrophilic grains

Primary Tauopathies (3R)

• Pick’s Disease: Frontotemporal dementia with behavioral changes and language impairment^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}6

Mixed Isoform Tauopathies

• Alzheimer’s Disease: Both 3R and 4R tau in neurofibrillary tangles

• Chronic Traumatic Encephalopathy: CTE shows 3R and 4R tau pathology, often with distinctive perivascular tau at the depths of sulci

Tauopathy Mechanisms in Neurodegeneration

Microtubule Dysfunction

Hyperphosphorylated tau loses its ability to bind and stabilize microtubules, leading to:

• Impaired axonal transport

• Cargo accumulation in axons

• Synaptic vesicle depletion

• Ultimately, axonal degeneration^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}7

Axonal Transport Impairment

Tau pathology disrupts both anterograde (kinesin-dependent) and retrograde (dynein-dependent) transport:

• Kinesin binding to tau competes with microtubule binding

• Tau accumulation leads to “traffic jams” in axons

• Mitochondria and other organelles cannot reach synaptic terminals^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}8

Synaptic Dysfunction

Tau aggregates at synapses contribute to:

• Presynaptic vesicle depletion

• Impaired neurotransmitter release

• Postsynaptic receptor mislocalization

• Early cognitive deficits before neuronal loss^{2Nat Rev Neurosci (2017)2017 · DOI 10.1038/nrn.2017.151Open reference}9

Neuronal Death Mechanisms

Multiple pathways lead to tauopathy-associated neuronal death:

• Apoptosis: Intrinsic pathway activation in tau-bearing neurons

• Necroptosis: RIPK1/3-mediated cell death in some tauopathies

• Autophagic cell death: Failed autophagy leading to aggregation

• Oxidative stress: Mitochondrial dysfunction and ROS accumulation

Genetic Factors in Tauopathies

MAPT Mutations

The MAPT gene on chromosome 17q21.31 encodes tau and numerous mutations cause or predispose to tauopathies^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}0. Over 50 pathogenic MAPT mutations have been identified:

Splicing mutations (alter tau isoform ratios):

• P301L/S: Most common, causes frontotemporal dementia with parkinsonism (FTDP-17)

• ** exon 10 + 16**: Causes 4R tau predominance

• ** exon 10 - 2**: Causes 3R tau predominance

Aggregation-promoting mutations:

• K280: Increases tau filament formation

• S305S: Affects exon 10 splicing

• Q336H: Enhances aggregation propensity

H1 Haplotype

The H1 haplotype of MAPT (a 500 kb inversion polymorphism) is strongly associated with PSP, CBD, and AGD^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}1. The H1c sub-haplotype specifically increases risk for PSP with an odds ratio of approximately 5.5. This haplotype influences MAPT expression and alternative splicing, favoring 4R tau production.

GWAS Findings

Genome-wide association studies have identified multiple tauopathy risk loci^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}2:

• MAPT: Strongest association (H1 haplotype)

• MOBP: Myelin-associated oligodendrocyte basic protein

• DUSP10: Dual specificity phosphatase 10

• SLCO1A2: Solute carrier organic anion transporter

• STX6: Syntaxin 6

Epigenetic Regulation in Tauopathy

DNA Methylation

Tauopathy is associated with widespread DNA methylation changes^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}3:

• Global hypomethylation in AD brain tissue

• Gene-specific changes at tau-related genes

• Age-related methylation drift exacerbates tau pathology

• APP promoter methylation affects amyloid processing

Histone Modifications

Histone acetylation and methylation patterns are altered in tauopathies:

• Reduced H3K9ac at synaptic genes correlates with cognitive decline

• Increased H3K27me3 at tau kinase promoters

• HDAC inhibitor therapy shows promise in preclinical models

Non-Coding RNAs

MicroRNAs (miRNAs) regulate tau pathology^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}4:

• miR-124: Reduced in AD; restores neuronal glutamate transport

• miR-132: Downregulated in tauopathy; regulates tau phosphorylation

• miR-219: Targets GSK3β mRNA

• miR-146a: Upregulated in AD; promotes inflammation

Long non-coding RNAs (lncRNAs):

• MALAT1: Altered in AD; regulates synaptic plasticity

• NEAT1: Promotes tau aggregation

Metabolic Dysfunction in Tauopathy

Glucose Metabolism

Tauopathy is closely linked to metabolic dysfunction^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}5:

• Brain glucose hypometabolism precedes clinical symptoms in AD

• Insulin signaling impairment exacerbates tau pathology

• Type 2 diabetes increases AD risk 1.5-2 fold

Key mechanisms:

• IRS-1 serine phosphorylation disrupts insulin signaling

• Akt/mTOR pathway dysregulation affects protein synthesis

• AMPK reduced activation impairs energy homeostasis

Mitochondrial Dysfunction

Mitochondria are severely affected in tauopathies:

• Reduced complex IV activity in AD and PSP

• Increased mtDNA mutations with age

• Impaired mitochondrial dynamics (fusion/fission)

• Tau accumulation in mitochondria disrupts function

Therapeutic implications:

• Mitochondrial antioxidants (MitoQ, CoQ10) being studied

• PGC-1α activators promote mitochondrial biogenesis

Insulin Signaling

Brain insulin resistance is a key feature^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}6:

• Intranasal insulin improves memory in AD trials

• GLP-1 agonists reduce tau phosphorylation in models

• SGLT2 inhibitors may provide neuroprotective effects

Sleep Disorders and Tauopathy

Bidirectional Relationship

Sleep disruption and tauopathy have a bidirectional relationship^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}7:

• Sleep deprivation increases CSF tau levels by 30-50%

• Tau pathology disrupts sleep-wake cycles

• Orexin system dysregulation contributes to sleep fragmentation

Circadian Rhythm Disruption

The suprachiasmatic nucleus is affected in tauopathies:

• BMAL1 clock gene expression reduced in AD

• Peripheral clock genes show altered rhythms

• Melatonin secretion declines with age and tauopathy

Therapeutic Implications

Sleep interventions may benefit tauopathy:

• Sleep hygiene improves tau clearance via glymphatic system

• Orexin antagonists (suvorexant) being studied

• Continuous positive airway pressure (CPAP) for sleep apnea improves cognition

Advanced Diagnostic Approaches

Tau PET Imaging

Tau PET ligands enable in vivo visualization of tau pathology^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}8:

FDA-approved ligands:

• Flortaucipir (AV-1451): Binds to PHF tau in AD

• PI-2620: Detects 3R and 4R tau

Emerging ligands:

• APN-1608: Superior off-target binding profile

• Lu-AV-145: Longer half-life for production

Limitations:

• Off-target binding to monoamine oxidase

• Variable binding in different brain regions

• Limited sensitivity for non-AD tauopathies

Cerebrospinal Fluid Biomarkers

CSF analysis provides molecular profiling^{3Mandelkow & Mandelkow, Cold Spring Harb Perspect Med (2012)2012 · DOI 10.1101/cshperspect.a006247Open reference}9:

Tau species:

• Total tau (t-tau): Marker of neuronal injury

• Phosphorylated tau (p-tau181, p-tau217, p-tau231): Disease-specific

• p-tau217/p-tau181 ratio: Differentiates AD from other dementias

Utility:

• p-tau217: High accuracy for AD diagnosis (AUC > 0.9)

• p-tau231: Tracks disease progression

• p-tau181: Predicts cognitive decline

Blood-Based Biomarkers

Emerging blood tests offer accessible diagnostics^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}0:

Key biomarkers:

• p-tau217: Plasma p-tau217 detects early AD

• p-tau181: FDA-approved blood test for AD

• NfL: Neurofilament light chain for neurodegeneration

Platforms:

• Simoa: Ultra-sensitive immunoassay

• Mass spectrometry: Precise tau species measurement

• IP-MS: Combined p-tau217/total tau ratio

Detailed Therapeutic Pipeline

Immunotherapy

Active vaccination:

• AADvac1: Phase 2, targets phospho-tau (Thr231)

• ACI-35: Liposome-based, targets phospho-tau (Ser396/404)

• Lu AF20513: Designed to induce antibodies to N-terminal tau

Passive immunotherapy:

• Gosuranemab (BMS-986168): Anti-N-terminal antibody, failed in PSP

• Semorinemab (RG6100): Anti-tau antibody, mixed results in AD

• Tilavonemab (ABBV-8E12): Anti-tau antibody, failed in PSP

• JAIKE (Lu AF87908): Targets early aggregate tau

Small Molecule Inhibitors

Tau aggregation inhibitors:

• Methylthioninium chloride (LMTM): Failed in Phase 3

• ** Davunetide**: Peptidyl-prolyl isomerase inhibitor

• Nicotinamide: SIRT1 activator

Kinase inhibitors:

• Tideglusib: GSK-3β inhibitor, failed in AD

• Saracatinib (AZD0530): Fyn inhibitor

• AMG-520: CDK5/p25 inhibitor

Microtubule Stabilizers

Paclitaxel derivatives:

• TX-2001: CNS-penetrant microtubule stabilizer

• NAP (davunetide): Octapeptide fragment of activity-dependent neuroprotective protein

Antisense Oligonucleotides

ASO therapy:

• IONIS-MAPTRx: Reduces MAPT mRNA, completed Phase 1/2

• ASO targeting exon 10 splicing: Reduce 4R tau

Gene Therapy

Viral vector approaches:

• AAV-MAPT: Express therapeutic tau variants

• CRISPR-based editing: Correct pathogenic mutations

• RNAi: Knockdown mutant tau expression

Animal Models of Tauopathy

Transgenic Models

3xTg-AD mice:

• APP, tau, and PS1 mutations

• Develops both amyloid and tau pathology

• Widely used for therapeutic testing

P301S tau mice:

• Express mutant human tau (P301S)

• Rapid NFT formation

• Used for immunotherapy testing

rTg4510 mice:

• Inducible tau expression

• Reversible tau pathology

• Allows study of tau clearance

Seeding Models

Inoculation studies:

• Brain homogenate from AD patients injected into mice

• Demonstrates prion-like propagation

• Used to study strain characteristics

Tau Propagation Models

Adeno-associated virus (AAV) models:

• AAV-tau injected into specific brain regions

• Spreads to connected regions

• Models tau network progression

Tau Propagation and Prion-Like Spread

Templated Aggregation

Tau exhibits prion-like properties^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}1:

• Seed-competent tau templated from patient brains

• Conformational templating converts normal tau to pathological forms

• Strain fidelity maintained in propagation

Intercellular Transfer

Tau spreads between neurons via:

• Synaptic transmission: Tau packaged in synaptic vesicles

• Extracellular vesicles: Exosomes carry tau

• Tunneling nanotubes: Direct cell-to-cell transfer

Network-Based Spread

Tau pathology follows brain networks:

• Connected brain regions show correlated pathology

• Vulnerable networks include default mode network

• Posterior-to-anterior progression in AD

Implications for Therapy

Therapeutic strategies targeting propagation:

• Anti-tau antibodies: Neutralize extracellular tau

• Aggregation inhibitors: Prevent seed formation

• Synaptic blockers: Inhibit trans-synaptic spread

Neuroinflammation in Tauopathy

Microglial Activation

Microglia play complex roles in tauopathy^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}2:

Pro-inflammatory (M1-like) microglia:

• Release cytokines (IL-1β, TNF-α)

• Exacerbate tau pathology

• Contribute to neuronal loss

Neuroprotective (M2-like) microglia:

• Phagocytose tau aggregates

• Release neurotrophic factors

• Promote tissue repair

Complement System

The complement cascade is heavily involved:

• C1q binds to tau aggregates

• C3 knockout reduces tau pathology

• CR3 mediates microglial phagocytosis

Cytokine-Mediated Effects

Key cytokines in tauopathy:

• IL-1β: Promotes tau phosphorylation via GSK-3β

• TNF-α: Disrupts synaptic function

• IL-6: Enhances tau aggregation

Therapeutic Targeting

Anti-inflammatory approaches:

• Minocycline: Broad microglial inhibitor

• TREM2 activation: Shifts microglia to protective phenotype

• NLRP3 inflammasome inhibitors: Reduce IL-1β production

Biomarkers

Imaging Biomarkers

• Tau PET ligands (Flortaucipir, PI-2620)

• MRI atrophy patterns

• Diffusion tensor imaging

Fluid Biomarkers

• CSF p-tau181, p-tau217, p-tau231

• Blood p-tau217, p-tau181

Cross-Links to Related Mechanisms

• Alzheimer’s Disease Mechanisms

• 4R Tauopathies (PSP, CBD) Mechanisms

• Tau Phosphorylation Pathway

• MAPT Gene

• Neurofibrillary Tangles

• Tau Immunotherapy

Vascular Contributions to Tauopathy

Cerebral Amyloid Angiopathy

Cerebral amyloid angiopathy (CAA) frequently co-occurs with tauopathy and contributes to disease progression^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}3. The accumulation of amyloid-beta in cerebral blood vessels not only increases hemorrhage risk but also disrupts vascular clearance pathways for both amyloid and tau. CAA-associated vascular dysfunction impairs the glymphatic system, reducing nocturnal clearance of toxic proteins from the brain interstitium.

Blood-Brain Barrier Breakdown

Tauopathy is associated with progressive blood-brain barrier (BBB) dysfunction^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}4. Pericyte loss and endothelial tight junction disruption allow peripheral proteins and immune cells to enter the brain, exacerbating neuroinflammation. BBB breakdown correlates with cognitive decline and predicts rapid progression in tauopathies.

Vascular Risk Factors

Hypertension, diabetes, and hyperlipidemia all accelerate tau pathology:

• Hypertension: Reduces cerebral blood flow, impairs tau clearance

• Diabetes: Promotes tau hyperphosphorylation via insulin signaling dysregulation

• Hyperlipidemia: Alters membrane composition, affects tau aggregation kinetics

Metal Ion Dysregulation

Iron Metabolism

Iron accumulation in the aging brain contributes to tau pathology through oxidative stress mechanisms^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}5. Excess iron catalyzes the formation of reactive oxygen species that promote tau phosphorylation and aggregation. Iron regulatory proteins (IRP1, IRP2) show altered expression in tauopathies, disrupting cellular iron homeostasis.

Zinc and Copper

Divalent metal ions directly influence tau aggregation:

• Zinc: Binds to tau at multiple sites, promotes aggregation at physiological concentrations

• Copper: Catalyzes oxidative modifications to tau, enhancing its aggregation propensity

Therapeutic Implications

Metal chelation therapy has been explored in tauopathies:

• Clioquinol: Copper/zinc chelator showed some cognitive benefit in Phase 2

• Deferoxamine: Iron chelator being studied for AD

• Novel chelators: CNS-penetrant compounds in development

Network Failure in Tauopathy

Default Mode Network Disruption

The default mode network (DMN) is particularly vulnerable in tauopathies^{4Nat Rev Neurosci (2016)2016 · DOI 10.1038/nrn.2016.38Open reference}6. Early tau accumulation in the entorhinal cortex and posterior cingulate disrupts DMN connectivity, correlating with episodic memory deficits. Functional connectivity changes precede structural atrophy, providing potential early biomarkers.

Tau and Brain Networks

Tau pathology spreads along connected neural networks:

• Connected regions show correlated tau deposition

• Synaptic activity promotes trans-synaptic tau spread

• Neuronal activity influences tau phosphorylation

Therapeutic Implications

Network-based approaches offer novel therapeutic strategies:

• Neural activity modulators: Reducing excitatory activity may slow spread

• Network-targeted interventions: Focused ultrasound, TMS

• Activity-dependent therapies: Environmental enrichment, cognitive training

Key Proteins and Genes

See Also

• Alzheimer’s Disease Mechanisms

• 4R Tauopathies (PSP, CBD) Mechanisms

• Tau Phosphorylation Pathway

• MAPT Gene

• Neurofibrillary Tangles

• MAPT

• GSK3B

• CDK5R1

• PPP2CA

• FYN

External Links

• PubMed

• KEGG Pathways